Shots:

• Lannett has provided an update on the clinical advancement of its biosimilar Insulin glargine. Following FDA meeting- Lannett has received FDA’s positive feedback on the clinical and CMC advancement of its biosimilar insulin glargine
• The company anticipates the filing of 351(k) biosimilar application for its biosimilar insulin glargine candidate by the end of 2022
• Lannett/HEC’s insulin glargine is a biosimilar to Sanofi’s Lantus (the reference biologic) and met its PK/PD safety endpoints in its study

Click here to read full press release/ article | Ref: PRNewswire | Image: Lannett